All Stories

  1. Re: “Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status” by Van Uytfanghe et al.
  2. Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study
  3. The Inter-dependence of the Limbs of Feedback Loops Affects the Regulation and Homeostasis of Multiple Physiological Systems.
  4. The role of supporting and disruptive mechanisms of FT3 homeostasis in regulating the hypothalamic–pituitary–thyroid axis
  5. Effects of aromatase inhibitor therapy on visceral adipose tissue area and cardiometabolic health in postmenopausal women with early and locally advanced breast cancer
  6. Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial
  7. Physiological linkage of thyroid and pituitary sensitivities
  8. Effects of estradiol on bone in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial
  9. Physiological Linkage of Thyroid and Pituitary Sensitivities
  10. Reduced upper limb lean mass on dual energy X-ray absorptiometry predicts adverse outcomes in male liver transplant recipients
  11. Principles of Endocrine Regulation: Reconciling Tensions Between Robustness in Performance and Adaptation to Change
  12. Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial
  13. Effect of estradiol on cognition in men undergoing androgen deprivation therapy: A randomized placebo‐controlled trial
  14. Effects of estradiol on fat in men undergoing androgen deprivation therapy: a randomized trial
  15. Treatment options for subclinical hypothyroidism
  16. Changes in white adipose tissue gene expression in a randomized control trial of dieting obese men with lowered serum testosterone alone or in combination with testosterone treatment
  17. Effect of Testosterone Treatment on Bone Microarchitecture and Bone Mineral Density in Men: A 2-Year RCT
  18. Global FT4 immunoassay standardization. Response to: Kratzsch J et al. Global FT4 immunoassay standardization: an expert opinion review
  19. Zoledronic acid does not affect insulin resistance in men receiving androgen deprivation therapy: a prespecified secondary analysis of a randomised controlled trial
  20. The Two Faces of Janus: Why Thyrotropin as a Cardiovascular Risk Factor May Be an Ambiguous Target
  21. Letter to the Editor: Hoermann Response to Fitzgerald et al. (DOI: 10.1089/thy.2019.0535)
  22. Who is afraid of non-normal data? Choosing between parametric and non-parametric tests: a response
  23. Differing Effects of Zoledronic Acid on Bone Microarchitecture and Bone Mineral Density in Men Receiving Androgen Deprivation Therapy: A Randomized Controlled Trial
  24. Comment on “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?”
  25. Heterogenous biochemical expression of hormone activity in subclinical/overt hyperthyroidism and exogenous thyrotoxicosis
  26. Reply
  27. Testicular volume and clinical correlates of hypothalamic–pituitary–testicular function: A cross-sectional study in obese men
  28. Triiodothyronine Secretion in Early Thyroid Failure: The Adaptive Response of Central Feedforward Control
  29. Functional and Symptomatic Individuality in the Response to Levothyroxine Treatment
  30. Handgrip Strength Adds More Prognostic Value to the Model for End‐Stage Liver Disease Score Than Imaging‐Based Measures of Muscle Mass in Men With Cirrhosis
  31. Individualised requirements for optimum treatment of hypothyroidism: complex needs, limited options
  32. Biomechanical Leg Muscle Function During Stair Ambulation in Men Receiving Androgen Deprivation Therapy
  33. Time for a reassessment of the treatment of hypothyroidism
  34. Reversible male hypogonadotropic hypogonadism due to energy deficit
  35. Use of Dual X‐ray Absorptiometry in men with advanced cirrhosis to predict sarcopenia‐associated mortality risk
  36. A body shape index (ABSI) reflects body composition changes in response to testosterone treatment in obese men
  37. Selective Loss of Levator Ani and Leg Muscle Volumes in Men Undergoing Androgen Deprivation Therapy
  38. Sensitivity of feedback control to thyroid reserve and modulation by FT3
  39. Lessons from Randomised Clinical Trials for Triiodothyronine Treatment of Hypothyroidism: Have They Achieved Their Objectives?
  40. Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial
  41. Editorial: “Homeostasis and Allostasis of Thyroid Function”
  42. Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer
  43. Mathematical Modeling of the Pituitary–Thyroid Feedback Loop: Role of a TSH-T3-Shunt and Sensitivity Analysis
  44. Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial
  45. Symptomatic Relief is Related to Serum Free Triiodothyronine Concentrations during Follow-up in Levothyroxine-Treated Patients with Differentiated Thyroid Cancer
  46. Homeostasis and Allostasis of Thyroid Function
  47. Recent Advances in Thyroid Hormone Regulation: Toward a New Paradigm for Optimal Diagnosis and Treatment
  48. TSH – an unreliable diagnostic test of of thyroid function
  49. Thyroid Allostasis – The Neglected Second Control Mode of Thyroid Function
  50. The effects of testosterone on body composition in obese men are not sustained after cessation of testosterone treatment
  51. Effects of androgen deprivation therapy on telomere length
  52. Dual control of pituitary thyroid stimulating hormone secretion by thyroxine and triiodothyronine in athyreotic patients
  53. Hypothalamic-Pituitary-Thyroid Axis Set Point Alterations Are Associated With Body Composition in Androgen-Deprived Men
  54. Effect of Testosterone Treatment on Adipokines and Gut Hormones in Obese Men on a Hypocaloric Diet
  55. Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial
  56. Relational Stability in the Expression of Normality, Variation, and Control of Thyroid Function
  57. Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy
  58. Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for end-stage liver disease score
  59. Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case-control study
  60. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer
  61. Cybernetic modelling of thyroid homeostasis for clinical trials and medical decision making
  62. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial
  63. High circulating oestrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease
  64. Letter to the Editor: Comment on “Reconciling the Log-Linear and Non-Linear Aspects of the TSH-Free T4 Relationship: Intra-Individual Analysis of a Large Population” by Rothacker K.M., et al.
  65. Correlation of visceral adipose tissue measured by Lunar Prodigy dual X-ray absorptiometry with MRI and CT in older men
  66. Reference range for TSH
  67. Low testosterone as a better predictor of mortality than sarcopenia in men with advanced liver disease
  68. Of rats and men: thyroid homeostasis in rodents and human beings
  69. Homeostatic Control of the Thyroid–Pituitary Axis: Perspectives for Diagnosis and Treatment
  70. Association of Sex Hormone Binding Globulin and Free Testosterone with Mortality in Men with Type 2 Diabetes Mellitus
  71. Variation in the biochemical response to l-thyroxine therapy and relationship with peripheral thyroid hormone conversion efficiency
  72. Variation in the Biochemical Response to L-Thyroxine Therapy and Relationship with Peripheral Thyroid Hormone Conversion
  73. Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes
  74. Integration of Peripheral and Glandular Regulation of Triiodothyronine Production by Thyrotropin in Untreated and Thyroxine-Treated Subjects
  75. Reference range for thyrotropin
  76. Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials
  77. Sex steroids levels in chronic kidney disease and kidney transplant recipients: associations with disease severity and prediction of mortality
  78. Response to Comment on Gianatti et al. Effect of Testosterone Treatment on Glucose Metabolism in Men With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2014;37:2098–2107
  79. Low-Serum Testosterone Levels Pre-Liver Transplantation Are Associated With Reduced Rates of Early Acute Allograft Rejection in Men
  80. Effect of Testosterone Treatment on Constitutional and Sexual Symptoms in Men With Type 2 Diabetes in a Randomized, Placebo-Controlled Clinical Trial
  81. TSH, FT4 and FT3 have individual, but interlocking roles in thyroid homeostasis
  82. Effect of Testosterone Treatment on Glucose Metabolism in Men With Type 2 Diabetes: A Randomized Controlled Trial
  83. Testosterone levels increase in association with recovery from acute fracture in men
  84. Do Thyroid-Stimulating Hormone, Body Weight, or Body Mass Index Serve as Adequate Markers to Guide Levothyroxine Dose Titration?
  85. Obesity and age as dominant correlates of low testosterone in men irrespective of diabetes status
  86. Mediterranean Diet for Primary Prevention of Cardiovascular Disease
  87. Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines
  88. Measurement of Total Rather Than Free Thyroxine in Pregnancy: The Diagnostic Implications
  89. Thyroid homeostasis results from multi-loop control
  90. Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study
  91. Determination of TSH levels may be inadequate for assessing thyroid function
  92. Low testosterone levels as an independent predictor of mortality in men with chronic liver disease
  93. TSH Measurement and Its Implications for Personalised Clinical Decision-Making
  94. Complex relationship between free thyroxine and TSH in the regulation of thyroid function
  95. Organkomplikationen der Hyperthyreose
  96. Clinical Relevance of Immunological Markers in Graves' Disease
  97. Stimulation of thyroidal and extrathyroidal thyrotropin receptors
  98. Course of thyroid nodules
  99. Treatment Regimens in Toxic and Diffuse Goiters in Iodine Deficiency
  100. Impact of Smoking on the Course of Graves' Disease after Withdrawal of Antithyroid Drugs
  101. Binding, Stimulating and Blocking TSH Receptor Antibodies to the Thyrotropin Receptor as Predictors of Relapse of Graves’ Disease after Withdrawal of Antithyroid Treatment
  102. Sensitive Thyrotropin and Thyrotropin-Receptor Antibody Determinations One Month After Discontinuation of Antithyroid Drug Treatment as Predictors of Relapse in Graves' Disease
  103. The human chorionic gonadotropin molecule from patients with trophoblastic diseases has a high thyrotropic activity but is less active in the ovary
  104. Amiodaron und Schilddrüsenfunktion
  105. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy
  106. Tumor- and Pregnancy-Derived Isoforms of Human Chorionic Gonadotropin: Biological and Diagnostic Relevance
  107. Thyroid-hormone suppressive therapy in benign thyroid nodules—is it effective?
  108. Relapse of Graves' Disease After Successful Outcome of Antithyroid Drug Therapy: Results of a Prospective Randomized Study on the Use of Levothyroxine
  109. Human chorionic gonadotropin exhibits normal biological activity in patients with recurrent pregnancy loss
  110. Maturation of Thyroidal Dendritic Cells in Graves' Disease
  111. Immunological and Biological Activity of Different Commercial Preparations of Human Chorionic Gonadotropin
  112. Long-Term Follow-up of Thyroid Nodule Growth
  113. Human chorionic gonadotropin exhibits normal biological activity in patients with recurrent pregnancy loss
  114. Posterior Retroperitoneoscopic Adrenalectomy: Lessons Learned within Five Years
  115. Second Generation Assay for Thyrotropin Receptor Antibodies Has Superior Diagnostic Sensitivity for Graves’ Disease
  116. Manual der Endokrinologie
  117. Diabetes mellitus
  118. Osteoporose
  119. Störungen der Nebennierenfunktion
  120. Störungen der Hypophysenfunktion
  121. Hypoglykämie
  122. Gonadotrope Funktion
  123. Hypoglykämie-Symptomenkomplex
  124. Corticotrope Funktion
  125. Schilddrüsenerkrankungen
  126. Allgemeine Hinweise zur Labordiagnostik
  127. Vorgehen bei ausgewählten Schilddrüsenerkrankungen
  128. Hypophysenhinterlappen
  129. Phäochromozytom
  130. Referenzbereiche endokrinologischer Laborparameter
  131. Erkrankungen der Schilddrüse
  132. Laktotrope Funktion
  133. Endokrinologische Anamnesebögen
  134. Primärer Hyperaldosteronismus
  135. Hirsutismus/Hyperandrogenämie
  136. Somatotrope Funktion
  137. Thyreotrope Funktion
  138. Störungen der sexuellen Differenzierung und der Sexualfunktion
  139. Störungen des Kalzium- und Knochenstoffwechsels
  140. Second Generation Assay for Thyrotropin Receptor Antibodies Has Superior Diagnostic Sensitivity for Graves' Disease
  141. Pre-Evaluation and System Optimization of the Elecsys® Thyroid Electrochemiluminescence Immunoassays
  142. T3-release from autonomously functioning thyroid nodules in vitro
  143. Regulation of Intercellular Adhesion Molecule-1 Expression in Human Thyroid Cells in Vitro and Human Thyroid Tissue Transplanted to the Nude Mouse in Vivo: Role of Graves' Immunoglobulins and Human Thyrotropin Receptor
  144. Regulation of Intercellular Adhesion Molecule-1 Expression in Human Thyroid Cellsin Vitroand Human Thyroid Tissue Transplanted to the Nude Mousein Vivo: Role of Graves’ Immunoglobulins and Human Thyrotropin Receptor1
  145. Cholesterol 7αHydroxylase Activity in Hypothyroidism and Hyperthyroidism in Humans
  146. Maligne Nebennierentumoren
  147. Expression of the human chorionic gonadotropin-beta gene cluster in human pituitaries and alternate use of exon 1.
  148. Immunochemical mapping of gonadotropins
  149. Expression of the human chorionic gonadotropin-beta gene cluster in human pituitaries and alternate use of exon 1
  150. Posterior Retroperitoneoscopy as a New Minimally Invasive Approach for Adrenalectomy: Results of 30 Adrenalectomies in 27 Patients
  151. Human Chorionic Gonadotropin-Beta in the Differentiation of Malignancy-Related and Nonmalignant Ascites
  152. Enhanced functional activity in thyroid adenomas in vitro
  153. Measurement of human chorionic gonadotropin-related immunoreactivity in serum, ascites and tumour cysts of patients with gynaecologic malignancies
  154. Variation in the thyrotropic activity of human chorionic gonadotropin in Chinese hamster ovary cells arises from differential expression of the human thyrotropin receptor and microheterogeneity of the hormone.
  155. Variation in the thyrotropic activity of human chorionic gonadotropin in Chinese hamster ovary cells arises from differential expression of the human thyrotropin receptor and microheterogeneity of the hormone
  156. Tumors of the Adrenals
  157. Immunoreactive human chorionic gonadotropin β core fragment in human pituitary
  158. Crude urinary human chorionic gonadotropin contains variant forms of HCG with low sialic acid content that exhibit an increased thyrotropic activity in CHO cells expressing the human TSH receptor
  159. Systemic iodine absorption during endoscopic application of radiographic contrast agents for endoscopic retrograde cholangiopancreaticography
  160. Interaction of human chorionic gonadotropin (hCG) and asialo-hCG with recombinant human thyrotropin receptor.
  161. Interaction of human chorionic gonadotropin (hCG) and asialo-hCG with recombinant human thyrotropin receptor
  162. Alpha-subunit and human chorionic gonadotropin-β immunoreactivity in patients with malignant endocrine gastroenteropancreatic tumours
  163. Increased binding capacity of receptors for the epidermal growth factor in benign thyroid nodules and thyroid malignancies
  164. Molecular heterogeneity of human chorionic gonadotropin in serum and urine from patients with trophoblastic tumors
  165. Thyroid stimulation by placental factors
  166. Inhibition of Functional and Immunological Responses to Thyroid-Stimulating Antibodies from Patients with Graves' Disease by Blockade of the Thyrotropin Receptor
  167. Role of Subunit Sialic Acid in Hepatic Binding, Plasma Survival Rate, and In Vivo Thyrotropic Activity of Human Chorionic Gonadotropin
  168. Clinical Use Of Hcg and hCGβ Determinations
  169. Clinical Use Of Hcg and hCGβ Determinations
  170. Antagonists of the Human TSH Receptor: In Vitro and in Vivo Studies of their Functional and Immunological Effects
  171. Gallstone ileus successfully treated by shock-wave lithotripsy
  172. Course of thyroid iodine concentration during treatment of endemic goitre with iodine and a combination of iodine and levothyroxine
  173. Asialoagalacto-human chorionic gonadotropin, a carbohydrate-modified variant of human chorionic gonadotropin, antagonizes the stimulatory actions of bovine thyroid-stimulating hormone on thyroid function and HLA-DR expression in human thyroid in vitro ...
  174. Carbohydrate Modifications Transform Human Chorionic Gonadotropin into a Potent Stimulator of Adenosine 3′,5′-Monophosphate and Growth Responses in FRTL-5 Thyroid Cells*
  175. Comparison of New and Conventional Assay Techniques for Measuring Thyroid Microsomal Antibodies
  176. Heterogeneity of Autoantibodies against Thyroid Peroxidase in Autoimmune Thyroid Disease: Evidence against Antibodies Directly Inhibiting Peroxidase Activity as Regulatory Factors in Thyroid Hormone Metabolism
  177. Evidence for the Presence of Human Chorionic Gonadotropin (hCG) and Freeβ-Subunit of hCG in the Human Pituitary
  178. Evaluation of the Ratio of T3 Release Stimulating Antibodies to TSH-Binding Inhibiting Antibodies during the Course of Graves' Disease
  179. Asialoagalacto-Choriongonadotropin, an Antagonist of the Action of Graves' Immunoglobulins in Human Thyroid Membranes with a Limited Affinity for Hepatic Receptors
  180. Insulin and insulin-like growth factor (IGF I) modulate the effects of bTSH on3H-thymidine incorporation in human thyroid cells in primary culture
  181. Inhibition of the cAMP response to Graves' immunoglobulins by recombinants of hCG in human thyroid membranes
  182. Design of a Long-Lived Thyrotropin Antagonist from Derivatives of Human Chorionic Gonadotropin*
  183. Evidence that Partially Desialylated Variants of Human Chorionic Gonadotropin (hCG) Are the Factors in Crude hCG that Inhibit the Response to Thyrotropin in Human Thyroid Membranes*
  184. Thyroid-stimulating antibodies in patients with long-term remission of Graves' hyperthyroidism
  185. Similar Triiodothyronine Releasing Activity of Thyroid Stimulating Antibodies in Human and Porcine Thyroid Slices
  186. Thyrotropic Activity of Acidic Isoelectric Variants of Human Chorionic Gonadotropin from Trophoblastic Tumors
  187. T3 releasing activity by Graves' sera from Graves' thyroid in vitro
  188. Thyrotropic Activity of Acid Isoelectric Variants of Human Chorionic Gonadotropin from Trophoblastic Tumors
  189. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease
  190. THYROID TEST STRATEGY
  191. Ketoconazole inhibits cortisol secretion of an adrenal adenoma in vivo and in vitro